Skip to main content Accessibility help
×
Home
Hostname: page-component-684899dbb8-rbzxz Total loading time: 0.709 Render date: 2022-05-23T07:59:50.402Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

23 - Management of cancer of the testis

Published online by Cambridge University Press:  05 November 2015

Jim Barber
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Satish Kumar
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bokemeyer, C. and Schmoll, H. J. (1995). Treatment of testicular cancer and the development of secondary malignancies. J. Clin. Oncol., 13, 283–292.CrossRefGoogle ScholarPubMed
Cullen, M. H., Stenning, S. P., Parkinson, M. C., et al. (1996). Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol., 14, 1106–1113.CrossRefGoogle Scholar
De Wit, M., Hartmann, M., Brenner, W., et al. (2006). [18F]-FDG-PET in germ cell tumors following chemotherapy: results of the German multicenter trial. J. Clin. Oncol., 24(18 Suppl.), 4521.Google Scholar
Fossa, S. D., Horwich, A., Russell, J. M., et al. (1999). Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J. Clin. Oncol., 17, 1146.CrossRefGoogle Scholar
Grimison, P. S, Stockler, M. R., Chatfield, M., et al. (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Ann. Oncol., 25, 143–148.CrossRefGoogle Scholar
Harland, S. J., Cook, P. A., Fossa, S. D., et al. (1998). Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J. Urol., 160, 1353–1357.CrossRefGoogle ScholarPubMed
Hendry, W. F., A'Hern, R. P., Hetherington, J. W., et al. (1993). Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br. J. Urol., 71, 208–213.CrossRefGoogle ScholarPubMed
Horwich, A., Oliver, R. T., Wilkinson, P. M., et al. (2000). A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br. J. Cancer, 83, 1623–1629.CrossRefGoogle ScholarPubMed
Huddart, R., O'Doherty, M., Padhani, A., et al. (2006). A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. J. Clin. Oncol., 24(18 Suppl.), 4520.Google Scholar
IGCCCG. (1997). International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol., 15, 594–603.
Lampe, H., Horwich, A., Norman, A., et al. (1997). Fertility after chemotherapy for testicular germ cell cancers. J. Clin. Oncol., 15, 239–245.CrossRefGoogle ScholarPubMed
Lorch, A., Kollmannsberger, C., Hartmann, J. T., et al. (2007). Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J. Clin. Oncol., 25, 2778–2784.CrossRefGoogle ScholarPubMed
Lorch, A., Bascoul-Mollevi, C., Kramar, A., et al. (2011). Conventional dose versus high dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumours, an international database. J. Clin. Oncol., 29, 2178–2184.CrossRefGoogle ScholarPubMed
Mead, G. M., Rustin, G. J., Stenning, S. P., et al. (2006). Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis. J. Clin. Oncol., 24 (18 Suppl.), 4519.Google Scholar
Oliver, R. T., Mason, M., Mead, G. M., et al. (2005). Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet, 366, 293–300.CrossRefGoogle Scholar
O'Sullivan, J. M., Huddart, R. A., Norman, A. R., et al. (2003). Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol., 14, 91–96.CrossRefGoogle ScholarPubMed
Parker, K., Smith, C. and Barber, J. (2011). Case series of 16 patients with stage II seminoma treated with sequential carboplatin AUC7 then para-aortic radiotherapy. Clin. Oncol. (R. Coll. Radiol.), 23, 70.Google Scholar
Patterson, H., Norman, A. R., Mitra, S. S., et al. (2001). Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother. Oncol., 59, 5–11.CrossRefGoogle ScholarPubMed
Pico, J. L., Rosti, G., Kramar, A., et al. (2005). A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumoursAnn. Oncol., 16, 1152–1159.CrossRefGoogle ScholarPubMed
Shahidi, M., Norman, A. R., Dearnaley, D. P., et al. (2002). Late recurrences in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer, 95, 520–530.CrossRefGoogle ScholarPubMed
Tandstad, T., Cavallin-Stahl, E., Dahl, O., et al. (2013). One course of adjuvant BEP in clinical stage I, nonseminoma: mature and expanded results from the SWENOTECA group. J. Clin. Oncol., 31 (Suppl.; abstr. 4553).Google Scholar
Tandstad, T., Cavallin-Stahl, E., Dahl, O., et al. (2014). Management of clinical stage I seminomatous testicular cancer: a report from SWENOTECA.J. Clin. Oncol., 32 (Suppl.; abstr. 4508).Google Scholar
Williams, S. D., Birch, R., Einhorn, L. H., et al. (1987). Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med., 316, 1435–1440.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×